NRx Pharmaceuticals Inc. (NRXP)
NASDAQ: NRXP
· Real-Time Price · USD
2.86
-0.05 (-1.72%)
At close: Sep 26, 2025, 11:08 AM
-1.72% (1D)
| Bid | 2.85 |
| Market Cap | 56.23M |
| Revenue (ttm) | 4K |
| Net Income (ttm) | -33.79M |
| EPS (ttm) | -2.21 |
| PE Ratio (ttm) | -1.29 |
| Forward PE | 3.08 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 2.88 |
| Volume | 94,805 |
| Avg. Volume (20D) | 414,868.3 |
| Open | 2.90 |
| Previous Close | 2.91 |
| Day's Range | 2.85 - 2.93 |
| 52-Week Range | 1.10 - 6.01 |
| Beta | 1.64 |
| Ex-Dividend Date | n/a |
About NRXP
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol NRXP
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for NRXP stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNRx Pharmaceuticals Inc. is scheduled to release its earnings on
Nov 13, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-1.9%
NRXP stock has given up its prior gain. NRX Pharma...
Unlock content with
Pro Subscription
1 month ago
-1.9%
NRX Pharmaceuticals shares are trading higher after the company announced the FDA has granted fast-track designation for NRX-100.
1 month ago · seekingalpha.com
NRx Pharmaceuticals, Inc. (NRXP) Q2 2025 Earnings Call TranscriptNRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q2 2025 Earnings Conference Call August 20, 2025 8:00 AM ET Company Participants Jonathan C. Javitt - Co-Founder, Chief Scientist Officer, Chairman & Interim C...